Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use

Table Of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
3 Therapeutic Landscape 11
3.1 Heart Failure 11
3.1.1 Symptoms 11
3.1.2 Etiology 12
3.1.3 Pathophysiology 12
3.1.4 Co-morbidities and Complications 12
3.1.5 Diagnosis 13
3.1.6 Classification 14
3.1.7 Prognosis and Disease Staging 14
3.1.8 Treatment Options 15
3.2 Myocardial Infarction 18
3.2.1 Symptoms 18
3.2.2 Etiology 18
3.2.3 Pathophysiology 18
3.2.4 Co-morbidities and Complications 19
3.2.5 Diagnosis 19
3.2.6 Classification 20
3.2.7 Treatment Options 21
3.3 Acute Coronary Syndrome 22
3.3.1 Symptoms 22
3.3.2 Etiology 22
3.3.3 Pathophysiology 23
3.3.4 Diagnosis 23
3.3.5 Treatment Options 24
4 Marketed Products 26
4.1 Heart Failure 26
4.2 Myocardial Infarction 26
4.3 Acute Coronary Syndrome 26
4.4 Key Marketed Products 26
4.4.1 Arixtra 26
4.4.2 Brilinta 28
4.4.3 Crestor 29
4.4.4 Diovan and Diovan HCT/Co-Diovan 30
4.4.5 Atacand 30
4.4.6 Lipitor 31
4.4.7 Clopidogrel bisulfate 32
4.4.8 Angiomax 32
4.4.9 Lovenox 33
4.4.10 Norvasc 34
4.4.11 Coreg 34
4.4.12 Ivabradine 36
4.4.13 Toprol-XL 36
5 Pipeline Analysis 38
5.1 Heart Failure Pipeline 38
5.1.1 Overall Pipeline 38
5.1.2 Pipeline Analysis by Molecule Type 39
5.1.3 Pipeline Analysis by Mechanism of Action 40
5.2 Myocardial Infarction Pipeline 41
5.2.1 Overall Pipeline 41
5.2.2 Pipeline Analysis by Molecule Type 42
5.2.3 Pipeline Analysis by Mechanism of Action 43
5.3 Acute Coronary Syndrome Pipeline 44
5.3.1 Overall Pipeline 44
5.3.2 Pipeline Analysis by Molecule Type 45
5.3.3 Pipeline Analysis by Mechanism of Action 46
5.4 Promising Drug Candidates in the Pipeline 47
5.4.1 LCZ-696 47
5.4.2 Darapladib (SB-480848) 48
5.4.3 Neucardin 49
5.4.4 Cangrelor 50
5.4.5 Serelaxin (Novartis AG) 50
6 Market Forecast to 2019 51
6.1 Asia-Pacific Market 51
6.1.1 Treatment Usage Patterns 51
6.1.2 Annual Cost of Therapy 51
6.1.3 Market Size 51
6.2 Australia 53
6.2.1 Treatment Usage Patterns 53
6.2.2 Annual Cost of Therapy 53
6.2.3 Market Size 53
6.3 China 55
6.3.1 Treatment Usage Patterns 55
6.3.2 Annual Cost of Therapy 55
6.3.3 Market Size 55
6.4 Japan 57
6.4.1 Treatment Usage Patterns 57
6.4.2 Annual Cost of Therapy 57
6.4.3 Market Size 57
6.5 India 59
6.5.1 Treatment Usage Patterns 59
6.5.2 Annual Cost of Therapy 59
6.5.3 Market Size 59
6.6 Drivers and Barriers for the Global Cardiovascular Diseases Market 61
6.6.1 Drivers 61
6.6.2 Barriers 62
7 Deals and Strategic Consolidations 63
7.1 Deals Analysis 63
7.2 Major Co-Development Deals 65
7.2.1 Genzyme Enters into Agreement with Osiris Therapeutics 66
7.2.2 Les Laboratoires Servier Enters into Co-development Agreement with miRagen Therapeutics 66
7.2.3 Cytokinetics Signs Strategic Agreement with Amgen 66
7.2.4 Biogen Idec Inc. Enters into Agreement with Cardiokine Inc. 66
7.2.5 Bristol-Myers Squibb Enters into Co-Development Agreement with Ambrx Inc. 67
7.2.6 Angioblast Systems Inc. Enters into Co-Development Agreement with Abbott India Limited 67
7.3 Major Licensing Deals 68
7.3.1 Cephalon Inc. Enters into Licensing Agreement with Mesoblast Limited for Regenerative Medicine 69
7.3.2 The Medicines Company Enters into Licensing Agreement with Pfizer Inc. 69
7.3.3 BioLineRx, Ltd. Enters into Licensing Agreement With Ikaria Holdings, Inc. 69
7.3.4 KAI Pharmaceuticals, Inc. Enters into Licensing Agreement with Bristol-Myers Squibb 69
7.3.5 Theravance, Inc. Enters into Licensing Agreement with Merck & Co., Inc. for Cardiovascular Therapeutic Candidates 70
7.3.6 Novartis AG Enters into License Agreement with Portola Pharmaceuticals, Inc. 71
7.3.7 Salix Pharmaceuticals, Ltd. Enters into License Agreement with Merck & Co, Inc. 71
7.3.8 Amgen Enters into Licensing Agreement with Cytokinetics 71
8 Appendix 72
8.1 All Pipeline Drugs by Phase 72
8.1.1 Preclinical 72
8.1.2 Pre-registration 76
8.1.3 Phase I 76
8.1.4 Phase II 78
8.1.5 Phase III 80
8.2 Market Forecasts to 2019 81
8.2.1 Global 81
8.2.2 Australia 82
8.2.3 China 83
8.2.4 Japan 84
8.2.5 India 85
8.3 Market Definitions 86
8.4 Abbreviations 86
8.5 Sources 88
8.6 Research Methodology 89
8.6.1 Coverage 89
8.6.2 Secondary Research 89
8.6.3 Primary Research 90
8.6.4 Therapeutic Landscape 90
8.6.5 Geographical Landscape 93
8.6.6 Pipeline Analysis 93
8.7 Expert Panel Validation 93
8.8 Contact Us 93
8.9 Disclaimer 93
List Of Table
1.1 List of Tables
Table 1: Cardiovascular Diseases Market, Asia-Pacific, General Symptoms of Congestive Heart Failure by Stage, 2013 11
Table 2: Cardiovascular Market, Global, Pharmaceutical Pipeline (Preclinical), 2013 72
Table 3: Cardiovascular Market, Global, Pharmaceutical Pipeline (Pre-registration), 2013 76
Table 4: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase I), 2013 76
Table 5: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase II), 2013 78
Table 6: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase III), 2013 80
Table 7: Cardiovascular Diseases Market to 2019, Heart Failure, Asia-Pacific, Market Forecast, 2012-2019 81
Table 8: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Market Forecast, 2012-2019 81
Table 9: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Market Forecast, 2012-2019 81
Table 10: Cardiovascular Diseases Market to 2019, Heart Failure, Australia, Market Forecast, 2012-2019 82
Table 11: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Australia, Market Forecast, 2012-2019 82
Table 12: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Australia, Market Forecast, 2012-2019 82
Table 13: Cardiovascular Diseases Market to 2019, Heart Failure, China, Market Forecast, 2012-2019 83
Table 14: Cardiovascular Diseases Market to 2019, Myocardial Infarction, China, Market Forecast, 2012-2019 83
Table 15: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, China, Market Forecast, 2012-2019 83
Table 16: Cardiovascular Diseases Market to 2019, Heart Failure, Japan, Market Forecast, 2012-2019 84
Table 17: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Japan, Market Forecast, 2012-2019 84
Table 18: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Japan, Market Forecast, 2012-2019 84
Table 19: Cardiovascular Diseases Market to 2019, Heart Failure, India, Market Forecast, 2012-2019 85
Table 20: Cardiovascular Diseases Market to 2019, Myocardial Infarction, India, Market Forecast, 2012-2019 85
Table 21: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, India, Market Forecast, 2012-2019 85
List Of Figures
1.2 List of Figures
Figure 1: Cardiovascular Diseases Market, Asia-Pacific, Heart Failure Treatment Algorithm, 2013 17
Figure 2: Cardiovascular Diseases Market, Asia-Pacific, Subtypes of Myocardial Infarction by Clinical Scenario, 2013 20
Figure 3: Cardiovascular Diseases Market, Asia-Pacific, Acute Coronary Syndrome Treatment Algorithm, 2013 25
Figure 4: Cardiovascular Diseases Market , Arixtra, Global, Annual Sales ($m), 2009-2012 27
Figure 5: Cardiovascular Diseases Market, Brilinta, Global, Annual Sales ($m), 2011-2012 28
Figure 6: Cardiovascular Diseases Market, Crestor, Global, Annual Sales ($m), 2009-2012 29
Figure 7: Cardiovascular Diseases Market to 2019, Lovenox, Global, Annual Sales ($m), 2009-2012 33
Figure 8: Cardiovascular Diseases Market, Coreg, Global, Annual Sales ($m), 2006-2012 35
Figure 9: Cardiovascular Diseases Market to 2019, Toprol-XL, Global, Annual Sales ($m), 2007-2012 37
Figure 10: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline, 2012 38
Figure 11: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline by Molecule Type, 2012 39
Figure 12: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline by Mechanism of Action, 2012 40
Figure 13: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline, 2012 41
Figure 14: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline by Molecule Type, 2012 42
Figure 15: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline by Mechanism of Action, 2012 43
Figure 16: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline, 2012 44
Figure 17: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline by Molecule Type, 2012 45
Figure 18: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline by Mechanism of Action, 2012 46
Figure 19: Cardiovascular Diseases to 2019, APAC, Market Size ($m), 2012-2019 52
Figure 20: Cardiovascular Diseases Market to 2019, Australia, Market Size ($m), 2012-2019 54
Figure 21: Cardiovascular Diseases Market to 2019, China, Market Size ($m), 2012-2019 56
Figure 22: Cardiovascular Diseases Market to 2019, Japan, Market Size ($m), 2012-2019 58
Figure 23: Cardiovascular Diseases Market to 2019, India, Market Size ($m), 2012-2019 60
Figure 24: Cardiovascular Diseases Market to 2019, Global, Deals, 2007-2013 64
Figure 25: Cardiovascular Market, Global, Co-development Deals, 2007-2013 65
Figure 26: Cardiovascular Diseases Market to 2019, Global, Licensing Deals, 2007-2013 68
Figure 27: GBI Research Market Forecasting Model 92

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.